Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Anti-Xa stability of diluted dalteparin for pediatric use.

Goldenberg NA, Jacobson L, Hathaway H, Tripputi M, Primeaux J, Child J.

Ann Pharmacother. 2008 Apr;42(4):511-5. doi: 10.1345/aph.1K609.

PMID:
18349310
2.

Low-molecular-weight heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review.

Ribic C, Lim W, Cook D, Crowther M.

J Crit Care. 2009 Jun;24(2):197-205. doi: 10.1016/j.jcrc.2008.11.002. Review.

PMID:
19327323
3.

Monitoring therapeutic anticoagulation with low molecular weight heparins: is it useful or misleading?

Hammerstingl C.

Cardiovasc Hematol Agents Med Chem. 2008 Oct;6(4):282-6. Review.

PMID:
18855641
4.

Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings.

Nutescu EA, Spinler SA, Wittkowsky A, Dager WE.

Ann Pharmacother. 2009 Jun;43(6):1064-83. doi: 10.1345/aph.1L194. Review.

PMID:
19458109
5.

Survival of heparins, oral anticoagulants, and aspirin after the year 2010.

Fareed J, Hoppensteadt DA, Fareed D, Demir M, Wahi R, Clarke M, Adiguzel C, Bick R.

Semin Thromb Hemost. 2008 Feb;34(1):58-73. doi: 10.1055/s-2008-1066025. Review.

PMID:
18393143
6.

[Advances in antithrombotic treatment--antithrombotics with anti-Xa effect].

Bátorová A.

Vnitr Lek. 2009 Mar;55(3):295-301. Review. Slovak.

PMID:
19378862
7.

New anticoagulants: focus on venous thromboembolism.

Gómez-Outes A, Lecumberri R, Pozo C, Rocha E.

Curr Vasc Pharmacol. 2009 Jul;7(3):309-29. Review.

PMID:
19601856
8.

New antithrombotic drugs: potential for use in oncology.

Levine MN.

J Clin Oncol. 2009 Oct 10;27(29):4912-8. doi: 10.1200/JCO.2009.24.7346. Review.

PMID:
19738103
9.

Bemiparin: second-generation, low-molecular-weight heparin for treatment and prophylaxis of venous thromboembolism.

Martínez-González J, Vila L, Rodríguez C.

Expert Rev Cardiovasc Ther. 2008 Jul;6(6):793-802. doi: 10.1586/14779072.6.6.793. Review.

PMID:
18570617
10.

Structure-activity relationships of low molecular weight heparins expose to the risk of achieving inappropriate targets in patients with renal failure.

Stratta P, Karvela E, Canavese C, Quaglia M, Lazzarich E, Fenoglio R, Pergolini P, Bellomo G, Cena T, Magnani C.

Curr Med Chem. 2009;16(23):3028-40. Review.

PMID:
19689280
11.

Heparin and low-molecular-weight heparin.

Gray E, Mulloy B, Barrowcliffe TW.

Thromb Haemost. 2008 May;99(5):807-18. doi: 10.1160/TH08-01-0032. Review.

PMID:
18449410
12.

Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review.

Huo MH, Muntz J.

Clin Ther. 2009 Jun;31(6):1129-41. doi: 10.1016/j.clinthera.2009.06.002. Review.

PMID:
19695383
13.

Low-molecular-weight heparin use in the obese, elderly, and in renal insufficiency.

Clark NP.

Thromb Res. 2008;123 Suppl 1:S58-61. doi: 10.1016/j.thromres.2008.08.005. Review.

PMID:
18809206
14.

Use of emerging oral anticoagulants in clinical practice: translating results from clinical trials to orthopedic and general surgical patient populations.

Merli G, Spyropoulos AC, Caprini JA.

Ann Surg. 2009 Aug;250(2):219-28. doi: 10.1097/SLA.0b013e3181ae6dbe. Review.

PMID:
19638915
15.

Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?

Fareed J, Iqbal O, Cunanan J, Demir M, Wahi R, Clarke M, Adiguzel C, Bick R.

Int Angiol. 2008 Jun;27(3):176-92. Review.

PMID:
18506123
16.

[Rivaroxaban: mode of action].

Drouet L.

Ann Fr Anesth Reanim. 2008 Dec;27 Suppl 3:S9-15. doi: 10.1016/S0750-7658(08)75141-4. Review. French.

PMID:
19185786
17.

Rivaroxaban: a novel, oral, direct factor Xa inhibitor.

Abrams PJ, Emerson CR.

Pharmacotherapy. 2009 Feb;29(2):167-81. doi: 10.1592/phco.29.2.167. Review.

PMID:
19170587
18.

Prevention of venous thromboembolism in the hospitalized medical patient.

Jaffer AK, Amin AN, Brotman DJ, Deitelzweig SB, McKean SC, Spyropoulos AC.

Cleve Clin J Med. 2008 Apr;75 Suppl 3:S7-16. Review.

PMID:
18494223
19.

Factor Xa inactivation in acute coronary syndrome.

Barantke M, Bonnemeier H.

Curr Pharm Des. 2008;14(12):1186-90. Review.

PMID:
18473865
20.

Ficts and facts of epinephrine and norepinephrine stability in injectable solutions.

Hoellein L, Holzgrabe U.

Int J Pharm. 2012 Sep 15;434(1-2):468-80. doi: 10.1016/j.ijpharm.2012.05.017. Review.

PMID:
22613065

Supplemental Content

Support Center